Rewiring Compulsion: A Biotech's Quest for Anorexia's First Targeted Drug

MONTRÉAL, QC – June 30, 2026 – In the world of psychiatric medicine, few conditions are as devastating and therapeutically barren as anorexia nervosa. Today, Montréal-based Will Therapeutics announced a significant step toward changing that narrative, securing a CAD $3.5 million, three-year research collaboration aimed at developing the first-ever targeted pharmacological treatment for the disorder.

Backed by the Government of Québec through the biopharmaceutical research consortium CQDM, the early-stage biotech company is partnering with the Douglas Hospital Research Centre to advance a novel class of brain-targeted small molecules. The project's goal is not merely to manage symptoms, but to address the underlying biology of habit and compulsion that drives the life-threatening illness.

“Will Therapeutics was founded to build a new category of medicine for compulsive disorders, beginning with anorexia nervosa,” said Benjamin Taylor, PhD, Chief Executive Officer of Will Therapeutics. “CQDM's support reflects the urgency of this mission and the strength of the underlying science, but the larger milestone is what it enables: advancing a program with the potential to become the first approved targeted pharmacological treatment for patients with anorexia nervosa.”

A Desperate Need for Innovation

To understand the significance of this announcement, one must first grasp the stark reality of anorexia nervosa. It is not a lifestyle choice or a simple fear of food; it is a complex psychiatric illness with the highest mortality rate of any mental disorder, stemming from medical complications of starvation and a high suicide rate. Yet, for the millions affected, the therapeutic toolkit is alarmingly sparse.

Currently, there are no medications approved by the FDA or Health Canada specifically for treating anorexia nervosa. The standard of care is a grueling, multidisciplinary effort combining intensive psychotherapy and nutritional rehabilitation. While approaches like Family-Based Treatment have shown success in adolescents, adults face a far more challenging path with high rates of relapse. Medications are used, but only off-label. Antidepressants like SSRIs may help with co-occurring depression or anxiety but are largely ineffective at promoting weight gain in severely underweight patients. Atypical antipsychotics are sometimes used to reduce obsessive thoughts and anxiety around eating, but their efficacy is modest and they come with a host of side effects. This leaves a vast, unmet medical need—a therapeutic desert that Will Therapeutics is venturing into.

Targeting the Biology of Habit

What makes Will Therapeutics' approach different is its fundamental premise: treating anorexia not just as a behavioral issue, but as a disorder of brain circuitry. The company is built on a new understanding of compulsion as a biological process—a dysfunction in the neural pathways that govern habit, reward, and cognitive control.

The research, led by Will's co-founder and McGill University professor Dr. Salah El Mestikawy, focuses on developing 'brain-penetrant small molecules'. These are precision-engineered compounds designed to cross the blood-brain barrier and interact with specific targets within the neural circuits implicated in compulsive behavior, such as the basal ganglia and prefrontal cortex. These are the brain regions where rigid, automatic habits can hijack goal-directed behavior.

Instead of the broad-stroke effect of an SSRI, which globally increases serotonin levels, this strategy is akin to neurochemical keyhole surgery. The goal is to modulate the specific neurochemical imbalances—involving neurotransmitters like dopamine and glutamate—that sustain the self-destructive patterns of anorexia. Dr. El Mestikawy's extensive background in the molecular mechanisms of neurotransmission provides the deep scientific credibility underpinning this ambitious endeavor. The company believes this approach, if successful, could not only break the cycle of compulsion in anorexia but also be extended to a wider family of related conditions, from obsessive-compulsive disorder (OCD) to other impulse control disorders.

Québec's Strategic Bet on Biotech

The CAD $3.5 million injection is more than just funding; it's a strategic endorsement from Québec's powerful life sciences ecosystem. CQDM, the consortium facilitating the grant, exists to bridge the perilous gap between promising academic research and commercially viable therapies. Its model involves using public funds to de-risk early-stage projects, making them more attractive for later-stage private investment.

By backing Will Therapeutics, CQDM and the Government of Québec are not only addressing a critical health crisis but also nurturing the province's position as a global biotech hub. This investment fosters local innovation, retains top scientific talent like Dr. El Mestikawy, and leverages the world-class research infrastructure at institutions like the Douglas Hospital Research Centre. It’s a calculated bet that a small Montréal startup could produce a globally significant medical breakthrough, generating both health and economic returns for the region.

The Long Road from Lab to Patient

While the announcement sparks hope, the road ahead is long and fraught with challenges. The journey from a promising small molecule in a lab to an approved drug in a pharmacy is a decade-long, billion-dollar marathon. Will Therapeutics' program is in the crucial early stages, and the CAD $3.5 million will support the foundational work needed to prepare for human trials.

The company must successfully navigate the rigorous three-phase clinical trial process. Phase I will test for safety in healthy volunteers, Phase II will assess efficacy and dosing in a small patient group, and Phase III will require large-scale trials to definitively prove the drug's benefit-risk profile to regulators. Psychiatric drug trials are notoriously difficult, challenged by the placebo effect and the complexity of measuring subjective outcomes.

However, the profound unmet need in anorexia nervosa could work in the company's favor, potentially earning it priority review from regulatory agencies if early data are compelling. For investors, patients, and the medical community, Will Therapeutics' journey represents a pivotal test case: can modern neuroscience finally deliver a targeted weapon against one of psychiatry's most intractable foes? The work starting now in Montréal could provide the first definitive answer.